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Rationale, aims and objectives: Adjuvant care for colorectal cancer (CRC) has increased
over the past 3 decades in South Australia (SA) in accordance with national treatment
guidelines. This study explores the (1) receipt of adjuvant therapy for CRC in SA as related to
national guideline recommendations, with a focus on stage C colon and stage B and C rectal
cancer; (2) timing of these adjuvant therapies in relation to surgery; and (3) comparative survival
outcomes.
Methods: Data from the SA Clinical Cancer Registry from 4 tertiary referral hospitals for
2000 to 2010 were examined. Patterns of care were compared with treatment guidelines using
multivariable logistic regression. Disease‐specific survivals were calculated by treatment
pathway.
Results: Four hundred forty‐three (60%) patients with stage C colon cancer and 363 (46%)
with stage B and C rectal cancer received guideline‐recommended care. While an overall increase
in proportion receiving adjuvant care was not evident across the study period, the proportion
having neoadjuvant care increased substantially. Older age was an independent predictor of
not receiving adjuvant care. Patients with stage C colon cancer who received recommended adju-
vant care had a higher 5‐year survival than those not receiving this care, ie, 71.2% vs 53.2%. Sim-
ilarly adjuvant therapy was associated with better outcomes for stage C rectal cancers. The
median time for receiving adjuvant care was 8 weeks.
Conclusions: Survival was better for stage C CRC treated according to guidelines. Adjuvant
care should be provided except where clear contraindications present. Other possible contribu-
tors to guideline adherence warranting additional investigation include co‐morbidity status, mul-
tidisciplinary team involvement, and choice.
KEYWORDS
adjuvant therapy, clinical cancer registry, clinical guidelines, colorectal cancer, survival, treatment1 | INTRODUCTION
Australia has one of the highest rates of colorectal cancer (CRC) in the
world, with CRC recorded as the second most common cancer and
cause of cancer death by Australian registries.1 Following worldwidewileyonlinelibrary.com/jouadvances in diagnostic technology, surgical technique, and adjuvant
therapy, CRC disease‐specific survivals have increased steadily1, with
5‐year survivals increasing from 48% in the 1980s to 66% in 2006 to
2010. Similar survival increases have been reported in South Australia
(SA), 1 of 8 Australian states and territories, which experience about© 2017 John Wiley & Sons, Ltd.rnal/jep 1
2 ADELSON ET AL.1240 new CRC diagnosed cases annually and approximately 450 CRC
deaths.2
International studies have indicated that 70% to 80% of newly
diagnosed CRC patients undergo curative resection, with 40% of them
developing incurable recurrent disease.3 Because patients with
resected colon cancer TNM stage III (Dukes stage C) and rectal cancer
stages II and III (Dukes stages B and C) are at increased risk of local and
distant recurrence, adjuvant therapy has been advocated since the
early 1990s.3,4
National treatment guidelines for CRC were first published in Aus-
tralia in 1999 and updated in 2005. They recommend that resected
stage C colon cancer receive adjuvant chemotherapy (postoperatively),
and resected stages B and C rectal cancer have chemoradiotherapy
although not specifying whether this adjuvant rectal cancer therapy
should be administered preoperatively or postoperatively (Figure 1).
Recommendations around the timing of adjuvant therapy were
included in an updated clinical review of these guidelines published
in 2014 by Cancer Council Australia (Figure 1).
The intention of guidelines is to guide, rather than enforce, and so
the extent of their uptake varies. A range of patient characteristics has
been previously described as possible contributors to variations in use
of adjuvant therapy.5,6 It is recognized that departures from guideline
recommendations can be appropriate, as for example, to accommodateFIGURE 1 Recommended national guidelines for adjuvant treatment of co
guidelines, and updated clinical review recommendations 2014cage‐related frailty, co‐morbidity, service access, and hospital factors.
Australian studies have reported old age and rural residence to be neg-
atively related to use of adjuvant therapies for CRC, after adjusting for
co‐morbidity.5,7,8 Factors affecting guideline uptake would also include
surgeon and patient choice.
In SA, information on CRC treatment is available through the
South Australia clinical cancer registry (SACCR). SACCR data have
shown a marked increase in use of adjuvant therapies since the
1980s. For stage C CRC cases, the proportion receiving this care
increased from 5% in 1980 to 1986 to approximately 60% receiving
this treatment for 2005 to 2010.2 However, a recent SA popula-
tion‐based data‐linkage study of CRC indicated that adjuvant
therapy was less common than advised in guidelines, particularly
for older patients.9
The present study aims to use SACCR data to explore guideline
implementation for adjuvant chemotherapy and/or radiotherapy
amongst patients with stage C colon and stages B and C rectal
cancers. Comparisons are made of adjuvant therapy use by
sociodemographic characteristics, the timing of adjuvant and neoadju-
vant therapies in relation to surgery, and survival outcomes in relation
to guideline‐recommended adjuvant therapies. Conduct of the study
was approved by the SA Health Human Research Ethics Committee
(HREC/14/SAH/174).lon stage C (III) and rectal stages B (II) and C (III) cancer: 1999a, 2005b
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2.1 | Data source and coding
The SACCR has collected clinical cancer data from major teaching hos-
pitals in SA since 1987. The data are compiled to monitor cancer stage
at diagnosis, other prognostic features, and treatment. Colorectal can-
cer treatment data were extracted from the SACCR database for the 4
tertiary SA referral hospitals that have cancer centres for the 2000 to
2010 diagnoses, with follow‐up to December 31, 2012. The data
included stage, grade, and treatment information. Cases were classi-
fied, according to the ICD‐O‐3 international classification of diseases
for oncology, in the C18‐20 range for CRC: C18 colon, C19‐20 for rec-
tum. The Australian Clinico‐Pathological Stage was recorded, which is
an extension of the original Dukes' staging to include metastatic dis-
ease. Pretreatment‐staging data are used in this study. For patients
with synchronous CRCs, the lesion with the more advanced stage
was used as the index cancer.
Radiotherapy, chemotherapy, and definitive CRC surgery dates
are recorded by the SACCR. As only start dates were available for adju-
vant therapies, it was not possible to determine whether radiotherapy
was short or long course. Chemotherapy and/or radiotherapy were
classified as adjuvant therapy if undertaken with curative intent and
commenced within 6 months of surgical treatment. Such therapies,
so close in time to the surgery and noted to be for curative intent on
the database, were assumed to be for adjuvant purposes rather than
a new event (eg, a recurrence or progression). Neoadjuvant therapy
was indicated where chemoradiation commencement preceded surgi-
cal treatment for stages B and C rectal cancer. Chemotherapy agents
used included 5FU and leucovorin, FOLFOX (with or without
bevacizumab), and capecitabine (with or without oxaliplatin).
Residential postcodes at diagnosis were used to assign geographic
socio‐economic status and remoteness/accessibility to services, using
the Australian Bureau of Statistics Socio‐economic Indexes for Area
and the Accessibility/Remoteness Index of Australia (ARIA),
respectively.
Concordance with guideline recommendations were assessed for
those Australian Clinico‐Pathological stages where the 2005 national
guidelines most strongly recommended use of adjuvant therapy, ie,
chemotherapy for stage C colon cancer and chemotherapy/radiother-
apy for stages B and C rectal cancers (Figure 1). The period between
the start of neoadjuvant or adjuvant therapy and definitive CRC sur-
gery was measured in days.2.2 | Analysis
Patterns of care were compared with the 2005 Australian treatment
guidelines, using binary analyses (χ2) and crude and adjusted multivar-
iable logistic regression. Candidate predictors of adjuvant therapies
used in analyses, selected a priori, included available
sociodemographic characteristics described above. Service site was
examined for potential confounding and effect modification and
was not found to differ significantly. As hospital was not a primary
variable of interest, the data presented are unadjusted for service
site. Any patient or sociodemographic variable potentially related toadjuvant therapy (as indicated by P < 0.20 in unadjusted analysis)
were entered into regression models with backwards elimination to
exclude non‐significant predictors (P < 0.05) that did not improve
model fit.
Disease‐specific survivals were calculated by person in patient
groups (colon or rectal) by receipt of adjuvant therapy, using Kaplan‐
Meier product‐limit estimates, with censoring of follow‐up on Decem-
ber 31, 2012. Cox proportional hazards regression analyses were also
used to compare disease‐specific survivals by stage and treatment,
using the same censoring rules. Stata 13 (StataCorp) was used for all
analyses.3 | RESULTS
There were 4273 people treated for CRC at these hospitals in 2000
to 2010. Treatment and sociodemographic characteristics are shown
in Appendix Table 1 (colon cancer, n = 2815) and Appendix Table 2
(rectal cancer, n = 1458). Adjuvant therapy was most common for
stage C colon cancer (n = 738 patients) and stages B and C rectal can-
cer (n = 792 patients), as recommended in guidelines. These stages
were the focus of further analysis (Figure 2). Residents of remote
and very remote areas were combined in analyses due to small
numbers.3.1 | Colon cancer treatment, stage C
Overall, the proportion of stage C colon cases receiving guideline‐rec-
ommended adjuvant (postoperative) chemotherapy was 60% (443/
738). The other 40% (293/738) had surgery alone (Table 1). This did
not vary significantly by hospital (P = 0.522) Cases from non‐metropol-
itan areas were more likely to receive chemotherapy (66%) than those
from metropolitan areas (57%). There was no significant difference in
proportions receiving adjuvant therapy by hospital, socio‐economic
index, diagnostic epoch (2000‐2004 vs 2005‐2010), or sex
(P > 0.100), but a decrease in receipt of adjuvant therapy applied for
increasing age when examined by 10‐year age groups from 40 to 80
+ (P < 0.000). Cases aged 50 to 59 years were the age group most likely
to receive adjuvant chemotherapy (90%), as compared with 70‐ to 79‐
year olds (63%) and 80+ year olds (14%), Table 1.
Multivariable logistic regression indicated that age groups 60 to
69, 70 to 79, and 80+ years were less likely to receive guideline‐rec-
ommended adjuvant care than those under 60 years of age. (Table 2).
Patients from areas classified as having moderate access to services
were also more likely than those from highly accessible areas to
receive this care (P = 0.007); however, the number of patients in this
category was small (n = 22). Mean time to receipt of adjuvant che-
motherapy was ≤8 weeks after surgery (mean 54 days, median
47 days). Seventy‐five percent received adjuvant therapy within
59 days of surgery.
There was a survival benefit for cases receiving adjunctive che-
motherapy (P < 0.001), with a 5‐year survival of 71.2% (95% CI,
66.2‐75.4) compared with 53.2% (95% CI, 46.6‐59) for other stage
C cases. The corresponding 10‐year survivals were 61.6% (95% CI,
55.7‐67.0) and 47.5% (95% CI, 40.0‐54.5) (Figure 3). This was also
TABLE 1 CRC surgically treated & receipt of recommended adjuvant therapy per 2005 national guidelines
Potentially Eligible for Adjuvant Therapy
(Strongly Recommended) Treatment Colon T = 738
Treatment Rectal T = 792
Stage C Colon and Stage B & C Rectal Cancers Stage C Stage B Stage C Total Rectal
n = 738 n = 351 n = 441 n = 792
Treatment n (%) n (%) n (%) n (%)
Surgery only 293 (39.7) 197 (56.1) 99 (22.4) 296 (37.4)
Surgery & chemo 430 (58.3) 23 (6.5) 110 (24.9) 133(16.8)
Surgery & radio 2 (0.3) 23 (6.5) 28 (6.3) 51 (6.4)
Surgery, radio, chemo 13 (1.8) 108 (30.8) 204 (46.3) 312 (39.4)
Total received adjuvant therapy per guidelinesa 443 (60.0) 131 (37.3) 232 (52.6) 363 (45.8)
Proportion of guideline adjuvant that was
Neoadjuvant chemo
12 (2.7) 79/131 (60.3) 113/232 (48.7) 192/363 (52.9)
Proportion of guideline adjuvant that was
Neoadjuvant radio
n/a 101/131 (77.1) 130/232 (56.0) 231/363 (63.6)
Year group 2000‐2004
Adjuvant per guidelines 184 (61.3) 60 (36.1) 96 (54.5) 156 (45.6)
No adjuvant per guidelines 116(38.7) 106 (63.9) 80 (45.5) 186 (54.4)
Total years 2000‐2004 300 (100) 166 (100) 176 (100) 342 (100)
Year group 2005‐10
Adjuvant tx per guidelines 259 (59.1) 71 (38.4) 136 (51.3) 207 (46.0)
No adjuvant tx per guidelines 179 (40.9) 114 (61.6) 129 (48.7) 243(54.0)
Total years 2005‐2010 438 (100) 185 (100) 265 (100) 450 (100)
Gender received Adjuvant tx per guidelines
Male 229/366 (62.6) 79/213 (37.1) 145/267 (54.3) 224/480(46.7)
Female 214/372 (57.5) 52/138 (37.7) 87/174 (50.0) 139/312(44.6)
Geographical
Metro adjuvant treatment per guidelines 291/509 (57.2) 85 (35.9) 152 (52.6) 237/526 (45.1)
Non‐metro adjuvant treatment per guidelines 152/229 (66.4) 46 (40.4) 80 (52.6) 126/266(47.4)
ARIA remoteness & adjuvant per guidelines
1 highly accessible 345 (57.7) 103 (37.3) 174 (51.9) 277/611 (45.3)
2 accessible 63 (68.5) 22 (40.7) 34 (54.0) 56/117 (47.9)
3 moderate accessible 22 (75.9) 1 (8.3) 17 (53.1) 18/44 (40.9)
4 remote and very remote 13 (68.4) 5 (55.6) 7 (63.4) 12/20 (60.0)
Age & Adjuvant therapy per guidelines
Adjuvant per guidelines <40 11 (78.6) 3 (100) 9 (64.3) 12/17 (70.6)
Adjuvant per guidelines 40‐49 29 (82.9) 12 (66.7) 23 (76.7) 35/45 (72.9)
Adjuvant per guidelines 50‐59 87 (89.7) 19 (43.2) 53 (60.2) 72/132 (54.6)
Adjuvant per guidelines 60‐69 130 (76.5) 42 (43.8) 71 (58.7) 113/217 (52.1)
Adjuvant per guidelines 70‐79 163 (63.2) 43 (36.1) 59 (47.0) 102/244 (41.8)
Adjuvant per guidelines 80+ 23 (14.0) 12 (16.9) 17 (27.0) 29/134 (21.6)
aAll stage C colon cancer cases should be considered for adjuvant chemotherapy (strongly recommended). All high‐risk rectal cases (stage B or C) should be
considered for adjuvant preoperative or postoperative radiotherapy (strongly recommended). Preoperative therapy may reduce the late morbidity compared
with postoperative (level 2, recommended).
4 ADELSON ET AL.demonstrated in the Cox model with adjuvant chemotherapy
independently associated with improved disease specific survival
(HR 0.56; 95%CI, 0.42‐0.75), Table 3.3.2 | Rectal cancer treatment, stages B and C
Overall, 45.8% (363/792) of cases with rectal cancer received guide-
line‐recommended adjuvant care; 39% (312/792) received combined
chemoradiotherapy adjuvant therapy, with a further 6% (51/363)
receiving adjuvant (n = 15) or neoadjuvant (n = 36) radiotherapy alone
(Table 1). Approximately 17% had surgery and chemotherapy withoutradiotherapy, of which nearly half (47%) were rectosigmoid cases. As
with colon cancer, the proportion receiving recommended adjuvant
care did not differ significantly by hospital (P = 0.522).
Rectosigmoid cancers constituted approximately a quarter
(n = 206, 26%) of rectal cases and were significantly less likely to
receive recommended radiotherapy (P < 0.001) with only 16% (33/
206) of them receiving radiotherapy as compared with 56% (330/
586) of rectal cases that were not in the rectosigmoid area. The pro-
portion of rectosigmoid cases that were stages B and C were similar
in profile to non‐rectosigmoid rectal cancers with 96/206 (47%) of
rectosigmoid cases being stage B and 110/206 (53%) being stage C.
TABLE 2 Factors for receipt of guideline‐recommended colorectal cancer adjuvant therapy, South Australia tertiary referral hospitals, 2000‐2010
Characteristics
(colon, stage C, n = 738)
Colon cancer (stage C)
univariate logistic
regression OR (95% CI) P value
Colon cancer (stage C)
adjusted logistic
regression OR (95% CI) P value
Gender: Male (ref) 1.0
Female 1.03 (0.74‐1.48) 0.852
Age Group: (ref <60) 1.0
60‐69 0.47 (0.26‐0.85) 0.013 0.47 (0.26‐0.86) 0.014
70‐79 0.25 (0.14‐0.43) <0.001 0.25 (0.14‐0.43) <0.001
80+ 0.02 (0.01‐0.04) <0.001 0.02 (0.01‐0.04) <0.001
ARIA remoteness:
Highly accessible (ref) 1.0
Accessible 1.47 (0.72‐3.01) 0.287 1.43 (0.83‐2.46) 0.194
Moderately accessible 4.40 (1.39‐13.89) 0.012 4.31 (1.50‐12.38) 0.007
Remote 1.76 (0.49‐6.30) 0.384
Area:
Metropolitan (ref) 1.0
Non‐metropolitan 0.99 (0.58‐1.72) 1.000
Year‐group: (ref 2000‐4) 1.0
2005‐2010 0.89 (0.62‐1.27 0.515
Characteristics (Rectal
cancer, n = 792)
Rectal Cancer (stage B & C)
univariate logistic regression
OR (95% CI)
Rectal Cancer (stage B & C)
adjusted logistic regression
OR (95% CI)
Gender: Male (ref) 1.0
Female 0.98 (0.72‐1.32) 0.902
Age Group: (ref <60) 1.0
60‐69 0.77 (0.51‐1.43) 0.194 0.76 (0.51‐1.36) 0.183
70‐79 0.51 (0.34‐0.75) 0.001 0.50 (0.34‐0.75) 0.001
80+ 0.20 (0.12‐0.33) <0.001 0.19 (0.12‐0.32) <0.001
ARIA remoteness:
Highly accessible (ref) 1.0
Accessible 1.07 (0.60‐1.93) 0.797
Moderately accessible 0.68 (0.32‐1.46) 0.325 0.64 (0.34‐1.21) 0.174
Remote 1.64 (0.59‐4.58) 0.342
Area:
Metropolitan (ref) 1.0
Non‐metropolitan 0.95 (0.58‐1.53) 0.827
Year‐group: (ref 2000‐4) 1.0
2005‐2010 0.99 (0.74‐1.33) 0.980
Stage (ref stage B) 1.0
Stage C 1.73 (1.29‐2.34) <.001 1.73 (1.28‐2.33) <.001
Abbreviations: CI, confidence interval; OR, odds ratio.
ADELSON ET AL. 5Although rectosigmoid cases were less likely to receive radiotherapy,
the results of the final logistic regression models were not affected
by including or excluding rectosigmoid cases.
Overall, patients with stage C rectal cancer were more likely to
receive guideline‐recommended adjuvant therapy (53%) than cases
with stage B (37%). As with colon cancer, there was no significant dif-
ference (P > 0.050) in the proportion who received adjuvant therapy by
hospital, socio‐economic index, sex, or diagnostic epoch. Cases from
non‐metropolitan areas were as likely to receive adjuvant therapy as
those from metropolitan areas (45% vs 44%, respectively). The propor-
tion treated by surgery alone was similar over time (39%, 135/342 for
2000‐2004, and 36%, 161/450 for 2005‐2010).As was the case with colon cancer, there was a lower receipt of
adjuvant therapy in older patients with rectal cancer (P < 0.001). When
examined by 10‐year age groups, the 40‐ to 49‐year age group was the
group most likely to receive adjuvant radiotherapy (73%, 35/45).
These findings were confirmed in the adjusted logistic regression
model, with the 2 oldest age groups, 70 to 79 and 80+, being signifi-
cantly less likely to receive adjuvant therapy after controlling for other
sociodemographic factors (Table 2).
Overall, most surgically treated cases received radiotherapy as
neoadjuvant therapy (64%, 231/363 of adjuvant therapy was before
surgery; Table 1). The proportion of adjuvant therapy that was neoad-
juvant was higher for stage B patients both for chemotherapy (60%)
FIGURE 2 Colorectal cases 2000 to 2010, South Australia clinical cancer registry, and receipt of adjuvant therapy
FIGURE 3 Colon cancer surgically treated stage C, receipt of GL
recommended adjuvant care, South Australia tertiary referral
hospitals, 2000 to 2010
TABLE 3 Hazard ratios (95% CI)* for death from colon cancer
Characteristics Colon, Stage C Hazard Ratio (95% CI) P value
Gender: Male (ref) 1.0
Female 0.97 (0.75‐1.24) 0.809
Age Group: (ref <60) 1.0
60‐69 1.05 (0.71‐1.57) 0.790
70‐79 1.08 (0.74‐1.58) 0.669
80+ 1.30 (0.84‐2.03) 0.231
Year‐group: (ref 2000‐4) 1.0
2005‐2010 0.88 (0.68‐1.14) 0.336
Treatment:
Surgery only (ref) 1.0
Surgery and chemo 0.56 (0.42‐0.75) <0.000
Abbreviation: CI, confidence interval.
*Adjusted for non‐significant (P > 0.05) associations with ARIA remoteness
and metropolitan area.
6 ADELSON ET AL.and radiotherapy (77%) when compared with stage C rectal cancers
(chemotherapy 49% and radiotherapy 56%; X2 4.5, P < 0.020 and X2
16.1, P < 0.001), respectively. The proportion of adjuvant therapy that
was neoadjuvant increased from 54%, 85/156, in 2000 to 2004 to
71.0%, 146/207, in 2005 to 2010 for radiotherapy, and for chemo-
therapy, from 43%, 67/156, to 60%, 124/207.
In a separate logistic model examining receipt of neoadjuvant ther-
apy amongst those receiving adjuvant therapy, the 2005 to 2010 diag-
nostic epoch was a significant predictor of receiving neoadjuvant care
and the age‐groups 70 to 79 and 80+ were significantly less likely to
receive neoadjuvant care than younger age groups (Table 4).The median time to adjuvant therapy after surgery was 48 days
for chemotherapy and 50 days for radiotherapy. Seventy‐five percent
of patients received adjuvant therapy within 67 days. For those
receiving neoadjuvant chemoradiotherapy, the median time to
surgery was 84 days. For those that were noted to have had only
neoadjuvant radiotherapy (with no recorded chemotherapy) and
rectal surgery (n = 36), the median time to surgery was 17 days. No
distinction was made in the dataset between short‐ and long‐course
radiotherapy schedules. The length of time for receipt of any adjuvant
therapy was similar for patients from metropolitan and non‐
metropolitan areas.
TABLE 4 Receipt of neoadjuvant therapy, rectal cancer, South Australia tertiary referral hospitals, 2000‐2010
Characteristics (Rectal
Cancer, n = 792)
Rectal Cancer (Stage B & C) Univariate
Logistic Regression OR (95% CI) P Value
Rectal Cancer (Stage B & C) Adjusted
Logistic Regression OR (95% CI) P value
Gender: Male (ref) 1.0
Female 0.85 (0.62‐1.17) 0.332
Age Group: (ref <60) 1.0
60‐69 0.74 (0.49‐1.11) 0.148 0.75 (0.49‐1.12) 0.160
70‐79 0.64 (0.43‐0.96) 0.032 0.64 (0.43‐0.95) 0.027
80+ 0.28 (0.16‐0.48) <0.001 0.27 (0.16‐0.47) <0.001
ARIA remoteness:
Highly accessible (ref) 1.0
Accessible 0.66 (0.36‐1.22) 0.189
Moderately accessible 0.39 (0.17‐0.94) 0.037 0.48 (0.22‐1.03) 0.059
Remote 0.87 (0.31‐2.47) 0.798
Area:
Metropolitan (ref) 1.0
Non‐metropolitan 1.18 (0.72‐1.93) 0.499
Year‐group: (ref 2000‐4) 1.0
2005‐2010 1.69 (1.22‐2.32) 0.001 1.70 (1.24‐2.34) 0.001
Stage (ref stage B) 1.0
Stage C 0.95 (0.69‐1.30) 0.747
Abbreviations: CI, confidence interval; OR, odds ratio.
ADELSON ET AL. 7No significant survival benefit was demonstrated comparing
those who did or did not receive recommended guideline treatment
in the Kaplan‐Meir survival curves for either stage B (P = 0.234) or
C (P = 0.614) rectal cancer (Figure 4). For those with stage C, the
5‐year survival was 69.4% (95% CI, 62.3‐75.3) compared with
68.2% (95% CI, 60.6‐74.6) for those who did not receive adjuvant
therapy. In the adjusted Cox proportional hazard model and when
compared with cases treated only by surgery, patients with stage
C rectal cancer receiving (neo)adjuvant chemotherapy had signifi-
cantly better survival outcomes than other stage C rectal cases
(hazard ratios 0.27; 0.16, 0.47), and also better survival outcomes
if they received chemotherapy and radiotherapy (hazard ratios
0.47; 0.30, 0.72), Table 5.FIGURE 4 Rectal cancer surgically treated stages B and C, receipt of
guideline (GL) recommended adjuvant care, South Australia tertiary
referral hospitals, 2000 to 20104 | DISCUSSION
This study uses the SACCR data to investigate differences in profiles of
patients according to whether they were receiving adjuvant therapy
for stage C colon and stages B and C rectal cancer in accordance with
the 2005 Australian CRC clinical practice guidelines.
Over the 10‐year study period, older age was a significant inde-
pendent predictor of not receiving adjuvant care. This was more appar-
ent amongst colon cases where significantly less received adjuvant
care after the age of 60, as compared with rectal cancer where the
drop‐off occurred in ages 70 and over. Differences by type of CRC
cancer were also evident in the overall proportion of patients receiving
stage‐specific adjuvant care; the majority of surgically treated patients
in SA teaching hospitals with colon cancer are receiving adjuvant ther-
apy (60%), but less than half (46%) of rectal patients are receiving this
treatment. However, with rectosigmoid cases excluded from the rectal
group, this proportion increases to 56%.
For those who did receive guideline‐recommended care, there
were significant stage specific survival benefits when compared with
those who did not receive this care. For stage C colon cases, receiving
adjuvant therapy was associated with higher survivals, consistent with
international and Australian literature.10,11 The decreased hazard ratio
for rectal cases receiving adjuvant therapy was also consistent with
trial results, despite the nonexperimental routine‐practice nature of
the treatment environment.12,13
Although our analyses were limited to the major public teaching
hospitals in SA, the proportion of patients receiving care is similar
to that reported in a population‐based linked SA study reporting
CRC outcomes. In that study, for those diagnosed from 2003 to
2008, 61% of stage C colon cancer patients received chemotherapy
and 35% of rectal stage B and 45% of rectal stage C cancer
TABLE 5 Hazard ratios* (95% CI) for death from rectal cancer
Characteristics Rectal Cancer Stage B Hazard Ratio (95% CI) P value Stage C Hazard Ratio (95% CI) P value
Gender: Male (ref) 1.0 1.0
Female 0.76 (0.46‐1.26) 0.288 0.69 (0.49‐0.99) 0.043
Age Group: (ref <60) 1.0 1.0
60‐69 1.83 (0.82‐4.04) 0.137 1.17 (0.73‐1.90) 0.511
70‐79 1.60 (0.71‐3.59) 0.252 1.27 (0.79‐2.03) 0.322
80+ 7.13 (3.01‐16.90) <.001 2.00 (1.17‐3.44) 0.011
Year‐group: (ref 2000‐4) 1.0 1.0
2005‐2010 0.65 (0.39‐1.08) 0.096 0.72 (0.51‐1.02) 0.069
Treatment:
Surgery only (ref) 1.0 1.0
Surgery & Radio 2.53 (1.09‐5.80) 0.029 1.07 (0.58‐1.97) 0.822
Surgery & Chemo 1.48 (0.50‐4.38) 0.479 0.27 (0.16‐0.47) <0.001
Surgery, Radio & Chemo 1.99 (1.12‐3.52) 0.018 0.47 (0.30‐0.72) 0.001
Abbreviation: CI, confidence interval.
*Adjusted for non‐significant (P > 0.05) associations with: ARIA remoteness and metropolitan area.
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registry data are probably a good proxy for state‐wide treatment
data. While one might expect the alignment of treatment with
guideline statements to be closer for major teaching institutions, it
is also possible that as major referral centres, they manage more
complex cases with higher levels of co‐morbidity where adjuvant
therapies may be contraindicated. Further, this could explain why
the few patients with colon cancer from the more geographically
remote areas were more likely to receive adjuvant care in the
adjusted logistic regression model. That is, they could have been
referred to the major referral centres, and as they lived >100 km
away, they would have been eligible for subsidized travel and
accommodation for the duration of their 5 to 6 weeks of adjuvant
therapy. Alternatively, this could be a spurious finding based on
low numbers in this category.
The proportion of patients receiving recommended adjuvant ther-
apy in our study was also similar with reported rates from other retro-
spective studies for these stages in Australia, eg, in the national CRC
concordance survey in 2000, recommended adjuvant therapy was
56% for colon cancer and 40% for postoperative chemoradiotherapy
for rectal cancers.14 In a 2006 to 2007 New South Wales study, 65%
of patients with colon cancer received adjuvant chemotherapy and
42% of patients with rectal cancer received radiotherapy.7 In a pro-
spective study from Victoria, the proportion of patients with stage C
colon cancer who received adjuvant therapy was 78%; however, all
patients in the study were discussed with or referred to a medical
oncologist.15 It is not known in our study what proportion of patients
was referred to oncologists.
In the most recent Australian survey of colorectal surgeons over
the period 2007 to 2014, only half of all rectal cancer cases reportedly
were discussed at multidisciplinary team (MDT) meetings, with special-
ist recommendations being an important predictor of treatment
choice.16 However, urgent presentations may preclude MDT opportu-
nities. An New South Wales study suggests that surgeons (as com-
pared with oncologists) acting as patient surrogates were less likely
to recommend adjuvant therapy;17although with the increased use ofMDTs, this is likely to be less of a factor. It is likely that increased
use of MDT decision‐making may be beneficial in supporting guide-
line‐recommended care for rectal cancers.6
The reasons for proportionally fewer rectal cancer cases receiving
adjuvant therapies are likely multiple, reflecting the greater case com-
plexities and morbidities associated with treating these cancers. Com-
bined modality treatment for rectal cancer increases both acute and
late morbidity, and tri‐modal treatment is often difficult for patients
to endure. Various chemoradiotherapy regimes have been the stan-
dard of care for rectal cancer since the 1990s, and lower concordance
is not surprising given conflicting information from trials and the large
volumes of evidence that need to be incorporated into decision mak-
ing.6,18,19 Furthermore, many guideline recommendations for patients
with high‐risk stage B/C rectal cancers are to generally treat them
alike. Many experts question whether these patients should be treated
collectively as not all stage B and C cases are at high risk. In addition,
the change from postoperative adjuvant to neoadjuvant chemoradia-
tion often leads to down staging and complicates postoperative histo-
pathology stage interpretation, which otherwise may have been more
relevant than preoperative staging.20 We were unable to determine
from our database whether there was a complete clinical response fol-
lowing neoadjuvant chemoradiation therapy for rectal cancer, although
it is possible that this may have applied for some of the patients who
did not have surgery following this treatment regimen.
The classification and treatment of upper rectal and rectosigmoid
cancers as a colon or rectal cancer can also affect interpretation of
need for adjuvant therapy as was evident in our study with only 16%
of these cancers receiving radiotherapy. In the 2010 national survey
of Australasian colorectal surgeons, 53% of surgeons reported that
they would not offer preoperative therapy for high‐risk upper rectal
cancer.18 It was noted in the survey that treatment differences in Aus-
tralasia may reflect varying radiological expertise in staging, patient
preferences, access to resources, and oncology unit practices.18 A
study in New South Wales elected not to include rectosigmoid cancers
when assessing receipt of adjuvant care due to controversies as to how
they should be treated.7
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the end of the postoperative era for rectal adjuvant therapy in the
mid‐2000s.3 Adjuvant therapy recommendations are based on trial evi-
dence, including evidence on whether preoperative radiation can be
omitted for selected patients,21 and non‐surgical chemoradiation pro-
vided with an otherwise “wait and watch” approach for locally
advanced rectal cancers.22,23 The capacity of clinical registries to mon-
itor these different radiotherapy regimes will be important in monitor-
ing and assessing evidence‐based clinical outcomes as they are put
into practice.
Clinical practice guidelines are not prescriptive, and reasons for
departing from guideline recommendations are multifaceted. Patient
characteristics such as disease stage, co‐morbidity status,
sociodemographic factors, and age all need to be considered.7,24
Undertreatment of older patients has been indicated in several Austra-
lian7,14,25 and international studies,24,25 with lower referrals and less
receipt of adjuvant therapy. However, there is evidence of change with
older patients now increasingly receiving adjuvant chemotherapy for
higher risk disease.
In this study, we lacked data on the numbers of patients offered
adjuvant therapy who refused it. Several studies have shown treat-
ment discordance of 10% to 20% associated with factors such as
increased age, co‐morbidity, and patient refusal.14,15,26,27 Capturing
this information in clinical cancer registries would provide important
insight into possible explanations around receipt of adjuvant care.
The optimal time interval from surgery to start of adjuvant therapy
has been evaluated in trials, with conflicting results. Recent studies and
a meta‐analysis suggest worse outcomes when adjuvant therapy for
stage C colon cancer is delayed for more than 8 to 12 weeks.28,29
Delayed initiation of adjuvant therapy is now being used as a key qual-
ity measure of care in Australia.30 In our study, most stage C colon can-
cer cases started adjuvant chemotherapy within the recommended
8 weeks of surgery.
For rectal cancers, the optimal interval to surgery with neoadju-
vant chemoradiotherapy or adjuvant radiotherapy has not been
established, although the Royal Marsden Hospital trial is evaluating
results and the French Greccar 6 trial has recently reported on inter-
vals ranging from 6 to 12 weeks.31 In the Greccar trial, there was a sig-
nificant increase in the overall morbidity rate in the 11‐week group (as
compared with the 7‐week group) due to complications.32 In our study,
rectal cases received this therapy within 8 weeks, consistent with cur-
rent practice evidence. Although we were not able to identify short‐
course radiotherapy within the historical SACCR registry system, it is
likely that some who received only neoadjuvant radiotherapy and rec-
tal surgery had short‐course therapy as the median number of days to
surgery following radiotherapy was 17 days. SACCR data from 2012
will be able to determine whether radiotherapy was short or long
course and whether there was a pathological complete response to
neoadjuvant therapy. These and other prognostic and treatment fac-
tors will be important in assessing outcomes of evolving rectal cancer
treatment regimens.
It is notable that the percentage of CRC cases receiving adjuvant
care remained fairly consistent over the 10‐year period. Potentially
closer guideline alignment could be achieved, with improved clinical
outcomes. Adjuvant therapies may be underused for both colon andrectal cancers, and routine reporting and monitoring should be under-
taken to address identified underuse. South Australia clinical cancer
registry data from the year 2011 will include details of treatment reg-
imens, reasons for receiving or not receiving surgical and adjuvant
therapies, and information on whether MDT reviews were completed.
With greater capacity to identify characteristics of those patients who
are not receiving adjuvant therapies in line with guideline statements,
efforts can be directed at exploring reasons and whether increased
use of adjuvant treatment is warranted. Clinician input into improved
data item collections including the additional information highlighted
from this study will be important in assessing new national treatment
guidelines for CRC currently being drafted.
Limitations of this study include a lack of information on patient
co‐morbidity and choice. Also, we did not have data regarding oncolo-
gist or surgeon recommendations for individual patients, and it could
be that older patients and their families are more likely to reject
multimodality treatment. This was a retrospective hospital‐based
study, and it could be that only the more complicated cases from
non‐metropolitan areas were seen at the major cancer centres and
thus treatment patterns for those from non‐metro areas are not
representative.
Notwithstanding the limitations of this study, there were several
important strengths. This included 10 years of clinical treatment infor-
mation from major referral centres, with little missing data. It provides
a benchmark on the timing and receipt of adjuvant therapy for CRC
against which future practices can be compared especially for older
age groups. With greater capacity to identify characteristics of those
patients who are not receiving adjuvant therapies in line with guideline
statements, efforts can be directed at exploring reasons and whether
increased use of adjuvant therapy is warranted. Future research should
include measures of morbidity and address any unwarranted dispar-
ities in cancer management.
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